Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings?

Core Insights - ANI Pharmaceuticals (ANIP) is scheduled to report its fourth-quarter and full-year 2025 earnings on February 27, with sales expected to be $233 million and earnings per share (EPS) at $1.99 [1][5] - The Zacks Consensus Estimate for 2025 EPS has slightly decreased from $7.55 to $7.53, while the estimate for 2026 has increased from $8.14 to $8.22 over the past month [1] Earnings Performance - ANI Pharmaceuticals has consistently exceeded earnings expectations in the last four quarters, achieving an average earnings surprise of 21.24%, with the most recent quarter showing a surprise of 17.24% [2][3] Sales Projections - The sales of Cortrophin Gel, a key product, are projected to reach $114 million, reflecting an 88% year-over-year growth [5][8] - The combined sales estimate for the recently acquired ophthalmology drugs, Iluvien and Yutiq, is $18.65 million, with unaudited sales figures reported at $19.8 million [9] - The generic segment is expected to see a decline in sales to $86 million due to increased competition [10] Valuation and Market Position - ANI Pharmaceuticals is trading at a price/sales (P/S) ratio of 1.98, which is below the industry average of 2.50 [5][13] - The company has outperformed the industry in stock price performance over the past year [11] Growth Outlook - The company is expected to maintain growth momentum in its rare disease portfolio, particularly with Cortrophin Gel and its ophthalmology products [15][16] - Despite competitive pressures in the generics segment, the company is positioned for reliable revenue growth through targeted launches and a strong manufacturing base [15] Competitive Landscape - ANI Pharmaceuticals faces competition in its rare disease portfolio, especially for Iluvien and Yutiq, from major pharmaceutical companies like AbbVie and Regeneron [17] - The primary competitor for Cortrophin Gel is Acthar Gel, marketed by Keenova Therapeutics [17]